For practice of precision medicine, non-invasive tools for diagnosing and prognostication at the molecular level are needed. Molecular imaging methods are capable of this while at the same time circumventing sampling error as the whole tumor burden is evaluated.
In Cluster for Molecular Imaging (CMI), we focus on translational molecular imaging with PET and PET/MRI and on development of targeted radionuclide therapies (theranostics) for use in precision medicine in cancer, cardiovascular diseases and inflammatory disease.
We have expertise in all the steps involved in developing molecular imaging: from basic research to obtaining approval by the health authorities, GMP and GCP. Access to both clinical and preclinical state-of-the-art facilities allow us to perform highly translational research based on relevant clinical challenges. Several of our results have been implemented in clinical routine.
The group is headed by Professor Andreas Kjær (MD, PhD, DMSc). Development of molecular imaging involves numerous disciplines; therefore, the group includes researchers from diverse backgrounds: physicists, chemists, engineers, human biologists, medical doctors, veterinarians, etc. We value a friendly, yet ambitious working environment where researchers can interact both professionally and socially.